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and anti-resorptive effects. However, we should not forget 
the systemic role now attributed to CKD-MBD. In fact, 
therapies targeting bone cells activity could also result in 
unpredicted extra-bone effects and affect cardiovascular 
outcomes. In conclusion, the new biologicals established 
for OP could be useful in renal patients with either OP or 
ROD. In addition, their potential non-bone effects warrant 
investigation.
Keywords Renal osteodystrophy · Osteoporosis · Mineral 
bone disorders · Bone mineral density · PTH 1–34 · 
Teriparatide · Denosumab · Romosozumab.
Introduction
The complex derangements in biomarkers of mineral 
metabolism occurring in chronic kidney disease (CKD) are 
invariably associated with bone abnormalities and extra-
skeletal calcification. These three aspects (laboratory, bone 
and vessels) are metabolically related and have been com-
bined in a new clinical condition named “CKD-mineral 
bone disorders” (CKD-MBD) [1]. The clinical spectrum 
of CKD-MBD goes beyond bone lesions to include an 
increased burden of morbidity and mortality for any cause 
or for cardiovascular disease. Thus the term renal osteod-
ystrophy (ROD) now indicates a single component of this 
“syndrome” [2], namely the bone pathology associated 
with CKD-MBD that develops as a consequence of chronic 
renal failure (CRF) [3]. Available histologic data of ROD 
are scarce and mostly limited to the overt, late stages of 
renal failure. Classical categories of ROD are high-turnover 
bone, low-turnover bone, osteomalacia and mixed uremic 
bone lesions. However, more recently a new classification 
of ROD has been proposed to take into account the three 
Abstract Renal osteodystrophy (ROD), the histologic 
bone lesions of chronic kidney disease (CKD), is now 
included in a wider syndrome with laboratory abnormali-
ties of mineral metabolism and extra-skeletal calcifications 
or CKD-mineral and bone disorders (CKD-MBD), to high-
light the increased burden of mortality. Aging people, fre-
quently identified as early CKD, could suffer from either 
the classical age-related osteoporosis (OP) or ROD. Distin-
guishing between these two bone diseases may not be easy 
without bone biopsy. In any case, besides classical thera-
pies for ROD, nephrologists are now challenged by the pos-
sibility of using new drugs developed for OP. Importantly, 
while therapies for ROD mostly aim at controlling parathy-
roid secretion with bone effects regarded as indirect, new 
drugs for OP directly modulate bone cells activity. Thus, 
their action could be useful in specific types of ROD. Para-
thyroid hormone therapy, which is anabolic in OP, could 
be useful in renal patients with low turnover bone disease. 
Denosumab, the monoclonal antibody against receptor acti-
vator of NF-κB ligand (RANK-L) that inhibits osteoclast 
activity and proliferation, could be beneficial in cases with 
high turnover bone. Use of romosozumab, the monoclonal 
antibody against sclerostin, which both stimulates osteo-
blasts and inhibits osteoclasts, could allow both anabolic 
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bone histologic parameters that are most relevant for bone 
mechanical and metabolic performances: turnover, miner-
alization and volume (the so-called “TMV” classification) 
[4]. Bone biopsy is the gold standard for determining the 
different types of ROD since the available biochemical 
markers [5] are not completely reliable.
Further, in recent years there has been increased atten-
tion to the early phases of CKD that are so commonly evi-
denced in elderly people. Some reduction in glomerular fil-
tration rate (GFR) invariably occurs with aging as a result 
of the physiologic reduction in the number of nephrons; 
however, the aging-related vascular disease or other 
nephropathies typical of aging may add further damage and 
lead to a further reduction of GFR. Since aging people also 
suffer osteoporosis (OP), we need to appreciate its coexist-
ence and interrelation with ROD. OP is defined as a condi-
tion of reduced bone strength predisposing to an increased 
risk of fracture [6], and is mostly diagnosed in the adult and 
aging population by the instrumental evidence of reduced 
bone mineral density (BMD) assessed by dual energy X-ray 
absorptiometry (DXA). Histologically, OP is characterized 
by a reduction of bone volume, but differs from ROD in 
that the defective mineralization processes are absent. For 
this reason, assessment of BMD in renal patients has been 
considered inadequate and discouraged until recently [3]. 
Accordingly, renal patients have been always diagnosed 
as affected with any type of ROD but not with OP. In fact, 
there is not still agreement on how to recognize OP in CKD 
[7]. Nonetheless, recent epidemiologic data demonstrated 
that CKD patients with reduced BMD suffer an increased 
risk of fracture and the eventual clinical burden of morbid-
ity and mortality [8]. Further, the wider clinical spectrum 
of CKD-MBD including not only ROD with its burden of 
fracture risk, but also the increased cardiovascular mortal-
ity, suggests that, in the early phases of CKD, we should 
search not only for mineral metabolism derangements and 
ROD but also for possible OP [9]. Indeed, the earliest meta-
bolic modification of mineral metabolism detectable in 
CKD seems to be a reduction in circulating soluble Klotho, 
which is a protein synthesized by renal tubular cells [10]. 
Klotho is the co-receptor of FGF23, the recently appreci-
ated bone hormone involved in the regulation of phosphate, 
vitamin D and parathyroid hormone, whose circulating lev-
els increase along with Klotho reduction [10]. These early 
alterations in Klotho and FGF23 are regarded as the very 
early disturbance of the bone-kidney cross-talk [11] which 
represents one of the pathophysiologic components of 
CKD-MBD. Accordingly, early changes in Klotho/FGF23 
could be helpful to distinguish patients with CKD and ini-
tial ROD from non-CKD pure OP patients. In addition, we 
could raise the question if there is a GFR threshold level 
for the switch from OP to ROD. Indeed, no reliable answer 
is available. We can speculate that, since FGF23 reflects 
bone cells activity, its early increments could be indicative 
of the adaptation of bone to CKD, and thus of the dawn of 
ROD. Accordingly, but speculatively, a threshold estimated 
GFR (eGFR) could be set at 60  ml/min. Indeed, a recent 
paper in OP men evidenced that higher FGF23 quartiles are 
useful predictors of incident fractures only in cases with 
 eGFRCrCys < 60  ml/min (a recognized GFR threshold for 
increments of FGF23) and not in the population as a whole 
[12].
These premises are necessary to highlight that ROD 
classification, either classical or TMV, is currently appre-
ciated mostly in advanced renal disease while some room 
should be found for OP, in particular in the early phases 
of CKD. Also, the epidemiologic evidence that a signifi-
cant reduction in BMD (diagnostic for OP) identifies CKD 
patients at increased risk of fracture [8, 13], and under-
lines the need for early therapy. Indeed, new therapies with 
drugs developed specifically for OP could be employed in 
CKD. Standard therapies for ROD mainly aim at improv-
ing the biochemical control of secondary hyperparathy-
roidism with the positive bone effects regarded as mostly 
indirect. At variance, new drugs developed to treat OP can 
directly modulate the activity of osteoblasts and osteoclasts 
and could thus represent new options to employ in CKD 
patients with either OP or ROD. Three drugs, in particular, 
merit attention from nephrologists: parathyroid hormone 
(PTH), denosumab and romosozumab. All of them have 
been successfully employed to increase BMD and reduce 
fracture rates in OP patients. The aim of this review is to 
examine the pharmacologic characteristics and clinical per-
formance of these three drugs in order to allow an appraisal 
of their possible use in CKD. For this reason, we will first 
recapitulate the pathophysiologic differences of bone in 
CKD and OP and will then consider, for each drug, the 
standard therapeutic indications and their potential role in 
CKD.
Bone physiology and alterations in CKD 
and osteoporosis
Bone is an endocrine organ whose cells constantly renew. 
In physiologic condition, there is a coordinated and per-
sistent process of bone resorption (worn bone) and bone 
formation (new bone) which needs to be well balanced 
(Fig. 1). Osteoclasts are responsible for resorption and oste-
oblasts for formation. Both processes are strictly regulated 
by hormones with paracrine or endocrine actions. Osteo-
clasts are members of the monocyte/macrophage family 
and bone marrow macrophages are their principal precur-
sors. Two cytokines are indispensable for osteoclastogen-
esis and osteoclast activation: receptor activator of NF-κB 
ligand (RANK-L) [14] and macrophage colony-stimulating 
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factor 1 (M-CSF) [15]. Osteoclast precursors express both 
RANK-L and M-CSF receptors (RANK and M-CSF-R, 
respectively) and, in the presence of M-CSF, RANK-L pro-
motes the differentiation of monocytes into mature bone-
resorbing osteoclasts. The major source of RANK-L and 
M-CSF are bone marrow stromal cells and their deriva-
tive osteoblasts [14]. Osteoblasts are also the main source 
of osteoprotegerin (OPG) production. OPG, a high-affinity 
ligand of RANK-L, acts as soluble inhibitor of RANK-L 
thus reducing osteoclast differentiation [16]. Finally, also 
osteocytes, the terminally differentiated osteoblast, are 
involved in regulation of bone turnover. In fact, they secrete 
both RANK-L and sclerostin. Sclerostin, an anti-anabolic 
protein, exerts its action by inhibiting the canonical Wnt 
(Wingless type mouse mammary tumor virus integration 
site) pathway. Sclerostin reduces osteoblastogenesis and 
promotes osteoblast and osteocyte apoptosis [17]. Moreo-
ver, sclerostin induces RANK-L synthesis and stimulates 
osteoclastogenesis. Both the RANK/RANK-L/OPG axis 
and Wnt-sclerostin pathway are now recognized as essen-
tial for the fine-tuned regulation of bone remodeling that 
needs to be well balanced (i.e. bone formation should equal 
bone resorption). Any uncoupling between resorption and 
formation leads to disease. In OP, for example, bone resorp-
tion prevails over bone formation thus leading to a progres-
sive reduction of bone mass and reduced bone strength. 
In ROD, the underlying metabolic derangements are more 
complex and involve bone cells activity and proliferation 
and the systemic balance in calcium and phosphate. Two 
hormones are classically involved with ROD development: 
parathyroid hormone and vitamin D. Parathyroid hormone 
secretion is typically increased in chronic renal failure 
(CRF) and produces a direct stimulation of bone cells, by 
activating its receptor, namely PTH receptor 1, on osteo-
blasts. This increases osteoblast maturation and activity, 
including an increased synthesis of the above-mentioned 
RANK-L, with eventual osteoclast activation. Also for vita-
min D, whose synthesis is mostly reduced in CRF, there is 
evidence of the influence of a specific receptor, the vitamin 
D receptor (VDR), on bone cells. Through this receptor, 
vitamin D directly modifies bone cells activity, indepen-
dently of other renal and intestinal actions affecting diva-
lent ions metabolism. In bone, vitamin D stimulates cal-
cium resorption [18] and osteoclast differentiation through 
induction of RANK-L synthesis [19]. Accordingly, the dif-
ferent types of ROD will develop depending on the prevail-
ing hormonal derangement. Table  1, which recapitulates 
Table 1  Derangements in bone turnover, mineralization and volume in ROD and in OP
ROD renal osteodystrophy, OP osteoporosis, T turnover, M mineralization, V volume
Classical definition T M V Definition
Renal osteodystrophy
 Osteitis fibrosa High Abnormal High/normal/low Increased bone remodeling with peritrabecular fibrosis. 
Increased number and activity of osteoclasts and 
osteoblasts
 Osteomalacia Low Abnormal Normal/low Defective mineralization of the organic matrix of bone
 Adynamic bone disease Low Normal/abnormal Normal/low Low bone formation, low number of bone cells
 Mixed uremic osteodystrophy High- normal Abnormal Normal/low Features of both osteitis fibrosa and osteomalacia
Osteoporosis
 High turnover OP High Normal Low Uncoupling of bone cells activity with prevailing 
resorption
 Normal/low turnover OP Low Normal Low Uncoupling of bone cells activity with prevailing low 
bone apposition
Fig. 1  Bone Remodeling. In physiologic condition, bone is continu-
ously renewed through the coordinated process of bone resorption by 
osteoclasts and bone formation by osteoblasts. Receptor activator of 
NF-κB ligand (RANKL) and osteoprotegerin (OPG), both produced 
by osteoblasts, are the key regulators of bone remodeling. RANK-L 
promotes the differentiation of osteoclasts’ precursor (OCs precursor) 
and pre-osteoclasts (Pre-OCs) in mature osteoclasts. OPG, a high-
affinity ligand of RANK-L, acts as a soluble inhibitor of RANK-L 
thus reducing osteoclasts differentiation. Osteocytes regulate bone 
turnover by secreting sclerostin (Scl). Sclerostin reduces osteoblas-
togenesis, promotes osteoblast and osteocyte apoptosis and, by induc-
ing RANK-L synthesis, stimulates osteoclastogenesis
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the main alterations in bone turnover, mineralization and 
volume associated with OP and ROD, summarizes the dif-
ferences and similarities existing between these two bone 
diseases.
Parathyroid hormone
Two biological PTH molecules are available for clinical 
use. One, the full-length recombinant human PTH (rhPTH 
1–84) is commercialized in the United States for patients 
with hypoparathyroidism and therefore we will not con-
sider it further. The other one, the N-term recombinant 
human PTH (rhPTH 1–34 or teriparatide), is produced by 
Escherichia Coli with recombinant DNA technology, con-
sists of the first 34 amino acids of endogenous PTH and has 
been approved since 2003 for the treatment of OP. Pharma-
cokinetics, contraindications, collateral effects, dosing and 
duration of therapy are schematically illustrated in Table 2. 
The presence in this molecule of the active N-term region 
of PTH suggests that all the biological actions of natural 
PTH are predictable. Therefore, to appreciate the potential 
of this drug, it may be useful to recall some essential infor-
mation about PTH, an 84-amino acid peptide secreted by 
parathyroid glands in response to the shifts in serum cal-
cium. Any decrease in serum ionized calcium stimulates 
PTH secretion, which in turn increases calcium reabsorp-
tion in the renal tubule and in bone [20]. Further, in renal 
tubular cells PTH stimulates the conversion of 25-hydrox-
yvitamin D to 1,25-dihydroxyvitamin D thus increasing 
intestinal calcium absorption [21]. Both actions aim at 
restoring serum calcium levels and at inhibiting, as a nega-
tive feed-back, PTH secretion. Natural circulating PTH 
comprises the intact molecule (PTH 1–84) and several 
amino (N)- and carboxy (C)-terminal fragments. The intact 
molecule and the N-terminal fragments (e.g. PTH 1–34), 
are active calcemic peptides since they bind to a specific 
PTH receptor, known as PTH1R [22], which is selective for 
the N-terminal region of the molecule [23] and expressed 
in the PTH target cells. At variance, the C-terminal frag-
ments do not bind to this receptor and have been since 
considered inactive. More recently, experimental evidence 
suggested that a paradoxical hypocalcemic activity could 
be exerted by the C-terminal fragments through a specific 
but still unidentified C-term PTH receptor (C-PTHRs) 
[24]. Another detail useful to appreciate the bone effects of 
PTH is that the PTH1R is expressed in osteoblasts but not 
in osteoclasts and that its activation increases osteoblasts’ 
Table 2  Comparison of the main pharmacologic and clinical differences among the three biological drugs examined
MW molecular weight, eGFR estimated glomerular filtration rate, OP osteoporosis, CKD chronic kidney disease, BMD bone mineral density
Teriparatide Denosumab Romosozumab
MW 4.1 kDa 35.4 kDa 145.9 kDa
Half life eGFR ≥ 60 ml/min/1.73 m2): 1.2 h
eGFR 30–59.9 ml/min/1.73 m2: 1.5 h
eGFR 15–29.9 ml/min/1.73 m2: 5 h
Normal renal function and CKD (stages 
1–5D): 25.4 days
Normal GFR: 6–9 days
Reduced GFR: No data available
Dosing Intermittent: 20 or 40 mcg/daily
Weekly: 56.5 mcg
OP: 60 mg every 6 months
Hypercalcemia or malignancy: 120 mg 
every 4 months
OP: 70–140 or 210 mg monthly 
or 140–210 every 3 months
Route of administration Subcutaneous Subcutaneous Subcutaneous
Duration of therapy Max 24 months 24 months 12 months
Side effects Short term hypercalcemia, hypercalciu-
ria, hyperuricemia, hypotension
Long term Osteosarcoma (in rats)
Skin reactions
Hypocalcemia
Skin reactions
Indications Severe OP
OP in patients intolerant or with con-
traindication to bisphosphonates
OP in patients unresponsive to other 
therapies
OP and high risk of fractures
OP in patients intolerant or with con-
traindication, or unresponsive, to other 
therapies
Hypercalcemia of malignancy refractory 
to bisphosphonates
Tumors: prevention of skeletal related 
events in patients with metastases
Post-menopausal OP (Phase III 
clinical studies)
Contraindications Hypercalcemic disorders
Predisposition to osteosarcoma
Primary or secondary hyperparathy-
roidism
Nephrolithiasis
Hypocalcemia
Vitamin D deficiency (replace with vita-
min D prior to administration)
Not available
Bone effect Anabolic Anti-resorptive Anabolic and anti-resorptive
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number and activity. Accordingly, an anabolic action is 
invariably attributed to PTH [25] (Fig. 2). However, follow-
ing activation, osteoblasts also increase RANK-L synthesis 
[26], which in turn will recruit new osteoclasts and activate 
them, thus balancing the two processes of bone formation 
and resorption. The final bone balance could nonetheless 
be affected by another characteristic of PTH hormone: 
its secretion is rhythmic and, with mechanisms still to 
be discovered, intermittent secretion is anabolic while 
chronic stable secretion is catabolic. Therefore, consider-
ing the short half-life of PTH, its daily administration as a 
drug resembles a pulsatile secretion and, not surprisingly, 
resulted in anabolic effects with increments in BMD in 
both preclinical [27, 28] and clinical studies [27, 28]. Also 
biochemical markers of bone formation like bone alkaline 
phosphatase and procollagen type I C-terminal propeptide 
(PICP) have been reported to increase [29]. Conceivably, 
since osteoblast stimulation by PTH eventually leads to 
osteoclast activation, as confirmed by the late increments 
of biomarkers of bone resorption [23], the initial increase 
in BMD could be caught up with by resorption in the long 
term. As a matter of fact, the stimulation of bone formation 
occurs earlier than bone resorption. Therefore, the rate of 
BMD increment is predictably higher in the first months of 
therapy and expected to plateau as also osteoclasts become 
recruited [23, 25, 29]. The final balance of BMD will reset 
at a value a little bit higher. On the contrary, chronic incre-
ments of PTH, like in primary hyperparathyroidism, may 
result in bone catabolism. Accordingly, the issue of the 
drug’s half-life may be essential when considering teripara-
tide use in renal patients.
Despite a powerful anabolic action when adminis-
tered once daily, PTH 1–34 is not a first-line therapy for 
OP due to its high costs, impractical route of administra-
tion and the consolidated experience with other common 
therapies. Teriparatide use is indicated for patients with 
severe primary or secondary OP (like glucocorticoid-
induced OP) and high risk of fracture who are intoler-
ant or unresponsive to standard therapies. Notably, the 
effect of PTH is dose dependent [29] and site specific. 
Trabecular bone increases more than cortical bone, as 
evidenced by the greater increase of BMD in trabecu-
lar sites (like vertebrae) compared to cortical regions 
(like radius) [30, 31]. PTH effects are not persistent 
since the BMD increment is lost after discontinuation of 
therapy, unless antiresorptive agents are administrated 
[32]. Pharmacokinetic studies in volunteers with CKD 
show an increased half-life along with GFR reduction, 
with the standard half-life of 1.2  h in normal subjects 
increasing up to 5  h in patients with GFR 15–30  ml/
min/1.73  m2 [33]. In any case, all teriparatide is elimi-
nated within 24  h. Safety and efficacy of teriparatide 
have been evaluated in a therapeutic trial involving 1637 
postmenopausal women with OP, aged 42–86 years, and 
whose serum creatinine at enrollment was ≤2 mg/dl. A 
further inclusion criterion was no increment in serum or 
urine calcium, or of PTH [34]. Patients were randomized 
to receive teriparatide (20 mcg or 40 mcg) or placebo 
and were arbitrarily divided into three groups of GFR: 
normal (GFR ≥ 80 ml/min/1.73 m2), mildly reduced GFR 
(50–79  ml/min/1.73  m2) and moderately reduced (GFR 
30–49  ml/min/1.73  m2). Patients with mild or moder-
ate renal impairment were older and with lower base-
line BMD (both neck and femoral). However, compared 
to placebo, teriparatide (either dose) increased lumbar 
spine BMD in each renal function subgroup, and femo-
ral neck BMD only in subgroups of normal and mildly 
reduced GFR. Fracture risk, both vertebral and non-ver-
tebral, was similarly reduced in patients with normal or 
reduced GFR. Treatment with teriparatide increased cir-
culating biomarkers of bone formation (amino-terminal 
peptide of procollagen type I, PINP), while markers of 
bone resorption were not analyzed in this study. Notably, 
patients with renal impairment experienced an increased 
incidence of hyperuricemia and, importantly, of hyper-
calcemia which, however, was always <11  mg/dl with 
the lower dose of 20 mcg. Notably, this study enrolled 
patients with BMD values diagnostic of OP and without 
overt hyperparathyroidism. However, since biochemical 
evidence of SHP may be subtle and difficult to recognize 
in the early phases of renal disease, the presence of ROD 
Fig. 2  Effects of PTH 1–34 on bone. Intermittent administration 
of recombinant human PTH 1–34 stimulates bone formation. The 
positive effect of intermittent PTH on bone appears to be mediated 
through the PTH-1 receptor (PTH1R), expressed only in osteoblasts. 
PTH1R activation increases osteoblasts’ number and activity. How-
ever, osteoblasts activation by PTH increases receptor activator of 
NF-κB ligand (RANK-L) synthesis and decreases osteoprotegerin 
(OPG) synthesis. This, in turn, leads to new osteoclasts recruitment 
and activation, thus balancing the two processes of bone formation 
and resorption. However, the increment in bone formation occurs ear-
lier than that of bone resorption, thus increasing bone volume in the 
first months of therapy before osteoclast activation
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instead of OP cannot be ruled out. Indeed, recent evi-
dence suggests that adynamic bone is the first manifesta-
tion of ROD, secondary to bone resistance to PTH in the 
early phases of renal failure [35, 36] and this should not 
be a contraindication to PTH therapy.
As for hemodialysis (HD) patients, the clinical experi-
ence with teriparatide is very limited. One study enrolled 
patients with a low concentration of PTH, low bone 
mass defined as low BMD at femoral, lumbar or distal 
one-third radio (T score ≤ −2.5), associated with a his-
tory of fragility fractures [37]. Teriparatide was admin-
istrated once-weekly (56.5 mcg) instead of the standard 
daily schedule and associated with increased lumbar 
spine BMD starting from week 24 and no changes in 
femoral BMD, thus confirming the site-specific effects. 
Markers of bone formation, such as PINP and bone alka-
line phosphatase (AP), increased early, while markers 
of bone resorption (tartrate-resistant acid phosphatase 
5, TRAP5b) gradually decreased. Serum PTH levels 
increased at week 4 and remained higher up to week 24. 
Notably, and at variance with data in non-dialysis renal 
patients, a reduction in serum calcium was also observed, 
even though in the absence of recorded symptoms.
In summary, in early to moderate CKD, teriparatide 
could reduce fracture risk and increase BMD of tra-
becular bone, in particular. This effect is most probable 
in postmenopausal women with mildly reduced GFR, 
low BMD and no biochemical evidence of SHP. In HD 
patients with low PTH and hypothetical adynamic bone, 
teriparatide could increase lumbar BMD. In theory, PTH 
therapy could be beneficial in the presence of low bone 
volume and turnover without osteomalacia, while it 
should be avoided in other types of ROD. Accordingly, 
we could try teriparatide mainly in patients with ady-
namic bone and low BMD. In any case, the complexity of 
bone metabolism in renal failure does not rule out a pri-
ori the use of this drug in renal patients even with moder-
ately increased PTH levels that do not exclude adynamic 
bone disease. Further, evaluation of systemic effects is 
warranted in renal patients, since PTH is not only a bone 
hormone, but also a uremic toxin whose levels are associ-
ated with mortality [38], and it is now acknowledged to 
be a stimulator of FGF23 [39] which, in turn, is a rec-
ognized inducer of left ventricular hypertrophy in uremia 
[40]. Absence of renal function carries with it potential 
problems which merit consideration. Since PTH pulsatile 
secretion is anabolic while chronic and stable increments 
are catabolic for bone, we can speculate that absence of 
renal function by prolonging the half-life of the drug 
could modify its efficacy. Further, drug metabolites with 
unpredicted actions could be produced, again affecting 
the final clinical result. Randomized clinical trials are 
warranted.
Denosumab
Denosumab is a human monoclonal IgG2 antibody, pro-
duced in mammalian cell lines by recombinant DNA tech-
nology, which targets and binds RANK-L with high affinity 
and specificity. RANK-L is a cytokine, member of the TNF 
superfamily, essential for osteoclastogenesis and osteoclast 
activation. RANKL also has a function in the immune sys-
tem, since it is expressed by T helper cells and is thought to 
be involved in dendritic cell maturation. RANK-L knock-
out mice develop severe osteopetrosis and low osteoclasts 
number but also defective T and B lymphocytes differen-
tiation [41]. Experimental inhibition of RANK-L with 
antibodies reduces osteoclast activity and survival with 
eventual reduction of bone resorption sites and increased 
BMD (Fig. 3). In animal models of OP [42] or of glucocor-
ticoid-induced OP [43], RANK-L inhibition reduced bone 
loss and increased BMD. Based on this experimental evi-
dence, a fully human monoclonal antibody to the RANK-L 
has been made available since 2010 for OP and glucocor-
ticoid-induced OP treatment. In postmenopausal women, 
denosumab significantly increased BMD by 9.2% at the 
lumbar spine and 6.0% at the total hip [44] and the incre-
ment was greater than with alendronate [45]. In addition 
to improving BMD, denosumab reduced fracture risk, at 
vertebral and non-vertebral sites [44]. To date, denosumab 
is not indicated as first-line osteoporosis treatment and its 
use is limited to patients intolerant or unresponsive to other 
standard therapies (such as bisphosphonates). In patients at 
high risk for fracture who also have impaired renal func-
tion, denosumab could be useful since, at variance with 
bisphosphonates, no dosage adjustment is required. In fact, 
Fig. 3  Effects of denosumab on bone. Denosumab targets and binds 
receptor activator of NF-κB ligand (RANK-L) with high affinity and 
specificity. RANK-L inhibition leads to suppression of osteoclasts 
differentiation, activity and survival. The final effect is the reduction 
of bone resorption sites and increased bone volume
Author's personal copy
J Nephrol 
1 3
a pharmacokinetic study in patients with different degrees 
of renal insufficiency showed no difference in serum con-
centration of denosumab along with reduction of GFR [46]. 
However, in renal patients episodes of hypocalcemia were 
more severe and prolonged than in subjects with normal 
renal function and were more likely in those with worse 
renal function [46]. This is consistent with a significant 
inhibition of osteoclast activity which, in renal patients 
with high PTH levels, is expected to lower not only serum 
calcium but also serum phosphate, similarly to parathyroid-
ectomy. The safety and efficacy of denosumab in patients 
with renal impairment have been evaluated in a post-hoc 
analysis of the Fracture Reduction Evaluation of Deno-
sumab in Osteoporosis Every 6 Months (FREEDOM) trial 
[44] involving 7808 postmenopausal women, 3902 treated 
with denosumab and 3906 with placebo. In the secondary 
data analysis, GFR was estimated with the Cockroft and 
Gault formula with the aim of evaluating if, in the different 
classes of GFR, there was a different efficacy [47]. Interest-
ingly, increments in BMD and incidence of adverse events 
(including changes in creatinine and calcium) did not differ 
by CKD stages. Anyway, in this analysis the distribution of 
cases within the different classes of GFR was not balanced 
(there was no patient in stage 5, 73 in stage 4, 2817 in stage 
3, 4069 in stage in 2 and 842 in stage 1) and the presence of 
kidney disease was not verified (no data provided on pro-
teinuria or urinary or kidney abnormalities). In addition, 
values of PTH were not reported nor was the type of bone 
disease verified (OP or ROD?). Accordingly, the conclu-
sions on safety and efficacy should be limited to postmen-
opausal women with GFR > 30  ml/min and without overt 
renal disease. In dialysis patients, the employment of deno-
sumab is very limited mostly due to the risk of severe and 
prolonged hypocalcemia. In a pilot study involving 12 HD 
patients diagnosed to have OP - based however, on calca-
neal ultrasound (US) T-Score values and not on standard 
DXA - the effect of denosumab was evaluated on US-BMD 
and fracture risk. Changes in both parameters were not sta-
tistically significant, but episodes of hypocalcemia were not 
severe and could be managed without clinical emergencies 
[48]. In another study, 24 HD patients affected by severe 
secondary hyperparathyroidism (PTH > 800  pg/ml) and 
low BMD (DXA T score < −2.5) received a single 60 mg 
subcutaneous (s.c.) dose of denosumab to evaluate the 
short-term effects of its co-administration with calcitriol 
on PTH and parathyroid glands. PTH levels and parathy-
roid gland volume significantly decreased in the treated but 
not in the control group (calcitriol therapy only) in which 
a progressive increase occurred [49]. Femoral neck and 
lumbar spine BMD also significantly increased. The most 
common adverse event in the treatment group was hypocal-
cemia, which occurred in spite of the concomitant increas-
ing doses of calcitriol, but for the most part it was sensitive 
to simple oral calcium supplements. Serum levels of phos-
phate also decreased. Notably in this study, the dose of cal-
citriol reached an average of 16 mcg/week for a few months 
and could thus be regarded as the drug responsible for the 
biochemical and instrumental changes described. Accord-
ingly, we should consider that in this study a major advan-
tage with denosumab was the reduction of serum levels of 
both calcium and phosphate which allowed to up-titrate the 
doses of vitamin D.
Table 2 schematically reports the indications, contrain-
dications, pharmacokinetic data, collateral effects, dos-
ing and standard duration of therapy with denosumab. As 
a whole, denosumab represents a potentially useful drug 
for bone disease in renal patients. However, we lack spe-
cific trials indicating the specific renal clinical conditions 
in which its advantages are superior to its potentially nega-
tive side effects. Moreover, given the antiresorptive action, 
its administration seems best indicated for patients with 
increased bone turnover or resorption, i.e. severe secondary 
hyperparathyroidism. Conceivably, while also patients with 
mixed lesions could gain from denosumab therapy, those 
with low turnover should not receive it. A specific point 
to appreciate and verify is that, given the long half-life of 
the drug, hypocalcemia (even asymptomatic) may be pro-
longed and cause parathyroid gland hypertrophy with the 
risk of rebound hyperparathyroidism. Further, a warning in 
general and in renal patients in particular could be neces-
sary regarding the non-bone related effects (on the immune 
system and inflammation). In particular, given the involve-
ment of the RANK/RANKL/OPG system with the process 
of calcification and with atherosclerosis [50], also these 
systemic effects should be considered.
Romosozumab
Romosozumab is a human monoclonal immunoglobulin 
(Ig)G2 antibody produced in a mouse cell line by recom-
binant DNA technology. It targets sclerostin thus exerting 
both anabolic and anti-resorptive actions (Fig.  4). Scle-
rostin is a 23 kDa glycoprotein produced by osteocytes that, 
by binding low density lipoprotein receptor related protein 
5/6 (LRP5/6) and its co-receptor frizzled, antagonizes the 
canonical, beta-catenin dependent, Wnt signaling in osteo-
blasts and inhibits bone formation [17]. The Wnt signaling 
pathway in osteoblasts is determinant to stimulate osteo-
blast differentiation and proliferation. Sclerostin, a Wnt 
antagonist, prevents bone formation by disabling the associ-
ation of Wnt ligands with their co-receptors. Sclerostin also 
increases RANK-L expression in osteoblasts and thereby 
stimulates osteoclastic bone resorption [51]. Indeed, scle-
rostin gene (SOST) knock-out mice and SOST inactivat-
ing mutations in humans [52, 53] are both characterized by 
increased bone formation and sclerosis of the skeleton [54]. 
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It can be noted that available drugs for OP treatment either 
inhibit bone resorption (bisphosphonates, denosumab) 
or increase bone formation (teriparatide), while the most 
powerful drug for OP would be one that both reduces bone 
resorption and stimulates bone formation, an effect theo-
retically obtainable by inhibiting sclerostin. Indeed, experi-
mental studies with anti-sclerostin antibodies, in different 
animal models, invariably demonstrated an increase in 
bone mass and an improvement in bone strength at all skel-
etal sites examined [55]. Histologically there was evidence 
of increased bone formation in trabecular, endocortical, and 
periostal surfaces with eventual increment of trabecular and 
cortical thickness. Further, the mineral apposition rate and 
mineralizing surfaces were also increased suggesting that 
sclerostin antibodies actually increased both activity and 
number of osteoblasts [54, 56]. Since a decrease of osteo-
clast surface was also observed, its anabolic effect did not 
lead to increased bone resorption. Pre-clinical observations 
also evidenced that the gain in bone mass was due to stimu-
lation of bone formation in the earlier period combined 
with reduced osteoclastic activity later on [57]. Romo-
sozumab is the first monoclonal humanized sclerostin neu-
tralizing antibody, developed to treat OP, for which we now 
have a phase III clinical study. The first placebo-controlled 
phase I trial, in human volunteers, enrolled 6 healthy men 
and 42 postmenopausal women [58]. They received single 
increasing doses of romosozumab subcutaneously (from 
0.1 to 10  mg/kg) or intravenously (1 or 5  mg/kg) or pla-
cebo and were then followed for 85 days for an analysis 
of safety, pharmacokinetics and pharmacodynamics. With 
the highest dose, bone formation markers (serum procol-
lagen type 1 N-propeptide or PINP, bone AP, and osteoc-
alcin) increased rapidly and progressively (+ 176%) and 
returned to baseline values after roughly 2 months. Bone 
resorption marker (serum C-telopeptide, CTX) decreased 
by a maximum 54% of baseline values 2 weeks after injec-
tion and returned to baseline after 2 months. Increment 
in PINP, bone AP, and osteocalcin and decrease in CTX 
were dose dependent. Similarly dose dependent was the 
increase in BMD, with the largest amount occurring in 
lumbar spine (5.3%) and total hip (2.8%) 85 days after a 
s.c. dose of 10  mg/kg. Non-linear pharmacokinetic pro-
files were recorded, with peak serum concentrations in 
the first week following s.c. administration. Further, in the 
highest s.c. and i.v. dose groups, serum concentrations of 
romosozumab declined biphasically. A single treatment-
related serious adverse event of non-specific hepatitis was 
reported. No death occurred. Mean serum ionized calcium 
transiently decreased by only 4%. The reduction was not 
associated with symptoms and calcium returned to baseline 
during the follow-up period.
A phase II, placebo-controlled study with romosozumab 
was conducted in 419 postmenopausal women, aged 55–85 
years, with low BMD (T score −2.0 or less at the lum-
bar spine, total hip, or femoral neck and −3.5 or more at 
each of the three sites) [59]. Participants were randomly 
assigned to receive romosozumab 70, 140, or 210 mg every 
month, or 140 or 210 mg every 3 months for 12 months. 
An open-label active comparator (alendronate or teripara-
tide) and a placebo group were also included. The pri-
mary end point was the percentage change from baseline 
in BMD at the lumbar spine at 12 months. Secondary end 
points included percent changes of BMD at other sites and 
of markers of bone turnover. At month 12, participants in 
the romosozumab group, compared to the placebo, had a 
significant increase in bone mineral density at the lumbar 
spine regardless of the dose or dose frequency. In addi-
tion, the romosozumab groups, compared to the placebo, 
had a significant increase in BMD at total hip and femoral 
neck. The largest BMD gain was observed with the 210 mg 
monthly dose which was significantly greater than that in 
the alendronate/teriparatide groups. Romosozumab was 
associated with a large increase in BMD at total hip and 
femoral neck. In all romosozumab groups, bone-formation 
markers (PINP, osteocalcin and bone AP) increased rapidly 
(at week 1), with peak increment at month 1, and returned 
to baseline or fell below baseline values between months 
2 and 9. The level of the bone-resorption marker CTX 
decreased rapidly (in the first week) and remained below 
baseline values at month 12. Finally, in the phase III, dou-
ble-blind, prospective, placebo controlled study, 7180 post-
menopausal women who had a T score of −2.5 to −3.5 at 
the total hip or femoral neck were enrolled [60]. The pri-
mary endpoint was the cumulative incidence of new verte-
bral fractures at 12 and 24 months. Secondary end points 
included non-vertebral and clinical fractures (a composite 
Fig. 4  Effects of romosozumab on bone. Romosozumab targets and 
binds sclerostin (Scl). Physiologically, Scl reduces osteoblastogenesis 
and promotes osteoclastogenesis. Thus, Scl inhibition leads to both 
anabolic (increased osteoblast activation) and anti-resorptive (reduced 
osteoclastogenesis) effects
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of non-vertebral and symptomatic vertebral). Patients were 
randomly assigned to receive subcutaneous injections of 
romosozumab 210 mg or placebo, monthly for 12 months; 
thereafter, both the placebo and the treatment group were 
shifted to an anti-resorptive drug, denosumab, administered 
as maintenance therapy, at the dose of 60 mg s.c., every 6 
months. At 12 months, the risk of new vertebral fracture 
was 73% lower in the romosozumab group. BMD increased 
at 6 months, and at 12 months the percent change was 
greater with romosozumab than with placebo at the lum-
bar spine, femoral neck and total hip. The bone-formation 
marker PINP increased rapidly in the romosozumab group 
(maximum peak on day 14) and returned to baseline levels 
by 9 months. The bone-resorption marker β-CTX decreased 
early during treatment (maximum decline on day 14) 
and, at 12 months, values were lower than in the placebo 
group. Serious adverse events that were potentially indica-
tive of hypersensitivity (dermatitis, allergic dermatitis, and 
macular rash) occurred in 7 patients in the romosozumab 
group. Injection-site reactions, mostly of mild severity, 
were reported in 187 patients (5.2%) in the romosozumab 
group and in 104 (2.9%) in the placebo group. Two events 
consistent with the definition of osteonecrosis of the jaw 
occurred in the romosozumab group only. The main phar-
macological and clinical data pertinent to romosozumab 
are summarized in Table 2.
As a whole, this monoclonal antibody against scle-
rostin increases bone formation, decreases bone resorp-
tion and lowers the risk of vertebral and clinical fractures 
in postmenopausal OP women. Theoretically, it could be 
employed also in renal patients, but no pharmacokinetics 
data are available in the presence of reduced GFR. Its spe-
cific anti-sclerostin action points to a useful employment in 
particular in cases with adynamic bone disease.
Another aspect to consider when dealing with this drug 
is the possibility of extra-skeletal effects, in particular on 
vascular calcification. Clinical observations in hemodialy-
sis patients showed higher serum sclerostin levels in those 
with aortic valve calcifications and upregulated sclerostin 
mRNA expression in calcified aortic valves explanted 
for clinical indications [61]. Similarly, in end-stage renal 
patients at time of transplantation, serum sclerostin cor-
related positively with vascular calcifications, but tissue 
expression of sclerostin was not evident in calcified epigas-
tric arteries [62]. We can speculate that higher circulating 
levels of sclerostin are associated with osteoblast inhibition 
and low bone turnover, and, hence, with vascular calcifi-
cations. Alternatively, increased tissue levels could inhibit 
calcification by inhibiting activity and trans-differentiation 
of the osteoblast-like cells (i.e. calcifying vascular smooth 
muscle cells) responsible for calcification. Therefore, the 
final effect of sclerostin inhibition with romosozumab on 
vascular calcification is not predictable. Its anabolic effect 
on adynamic bone could improve calcium and phosphate 
balance and then vascular calcification, while local reduc-
tion could favor it. In any case, romosozumab by interact-
ing systemically and/or locally with the RANK/RANKL/
OPG system and the Wnt pathway could definitely affect 
vascular calcifications and mortality [61, 63]. Accordingly, 
the link between vascular calcification and romosozumab 
therapy must be regarded as a new, still unexplored, field of 
clinical research.
Future perspectives
Teriparatide, denosumab and romosozumab are very new 
drugs for the nephrologist. They modify the activity of the 
individual bone cells and can drive their normally coupled 
activity toward different balances. Nephrologists should 
quickly learn if and how to employ them in specific ROD 
types. Specifically, since the most frequent bone lesion 
described in CKD-5D patients is low turnover bone and 
since we can generally cure high turnover bone through 
medical or surgical therapy, a “wish come true” trial could 
focus attention on adynamic bone disease. One could pro-
pose an ideal prospective randomized trial exploring hard 
outcomes (fractures, vascular calcifications and cardio-
vascular mortality) in incident dialysis patients with bone 
biopsy-proven adynamic bone and randomized to standard 
therapies (placebo) or teriparatide for 1 year, followed by 
denosumab for a second year. Alternatively, also romo-
sozumab could be employed, but we lack any available 
clinical evidence for its use in renal patients.
Conclusions
Bone disease in renal patients has now clearly become 
transformed into a complex bone endocrinopathy at the 
heart of CKD-MBD, with a significant potential link to car-
diovascular disease. The new biologicals established for OP 
have direct effects on the activity of bone cells with effects 
that could be tailored for the treatment of some specific 
ROD types. However, the evaluation of systemic effects 
is also warranted, given the complexity of bone disease in 
renal failure.
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